PLGA nanocapsules improve the delivery of clarithromycin to kill intracellular Staphylococcus aureus and

Frantiescoli Anversa Dimer1, Cristiane de Souza Carvalho-Wodarz1, Adriely Goes2

  • 1Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Saarland University, Saarbrücken, Germany.

Insights

Novel nanocapsules effectively deliver clarithromycin to target intracellular Staphylococcus aureus and Mycobacterium abscessus infections. This antibiotic drug delivery system shows significant potential for treating challenging bacterial infections.

Area of Science:

  • Pharmacology
  • Nanotechnology
  • Infectious Diseases

Background:

  • Drug delivery systems offer targeted antibiotic delivery to infection sites.
  • Intracellular pathogens like Staphylococcus aureus and Mycobacterium abscessus pose treatment challenges.

Purpose of the Study:

  • To develop and evaluate PLGA nanocapsules for aerosol delivery of clarithromycin.
  • To assess the efficacy of nanoencapsulated clarithromycin against intracellular S. aureus and M. abscessus.

Main Methods:

  • Encapsulation of clarithromycin in PLGA nanocapsules for aerosolization.
  • In vitro testing against intracellular S. aureus and M. abscessus in cell cultures.
  • In vivo studies using a murine wound model and zebrafish.
  • Assessment of drug permeability across Calu-3 cell monolayers.

Main Results:

  • Nanoencapsulation reduced intracellular S. aureus by 1000-fold compared to free clarithromycin.
  • Clarithromycin nanocapsules demonstrated 70-80% killing efficacy against M. abscessus.
  • In vivo studies confirmed efficacy against S. aureus.
  • Improved permeability of nanocapsules suggests enhanced delivery to sub-epithelial tissues.

Conclusions:

  • Clarithromycin-loaded PLGA nanocapsules are a promising strategy for targeting intracellular S. aureus and M. abscessus.
  • Aerosol delivery of nanoencapsulated clarithromycin enhances antibiotic efficacy.
  • This approach may overcome limitations of conventional antibiotic treatments for intracellular infections.

Related Concept Videos

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
166
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.7K
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
156